COCP — Cocrystal Pharma Income Statement
0.000.00%
Last trade - 00:00
- $14.75m
- -$11.60m
- 15
- 47
- 34
- 23
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.56 | 2.01 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 55 | 11.6 | 14.2 | 38.8 | 18.6 |
Operating Profit | -48.4 | -9.59 | -14.2 | -38.8 | -18.6 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -48.2 | -9.65 | -14.2 | -38.8 | -18 |
Provision for Income Taxes | |||||
Net Income After Taxes | -48.2 | -9.65 | -14.2 | -38.8 | -18 |
Net Income Before Extraordinary Items | |||||
Net Income | -48.2 | -9.65 | -14.2 | -38.8 | -18 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -48.2 | -9.65 | -14.2 | -38.8 | -18 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.778 | -2.1 | -1.93 | -2.23 | -2.13 |